©The Author(s) 2026.
World J Diabetes. Jan 15, 2026; 17(1): 111165
Published online Jan 15, 2026. doi: 10.4239/wjd.v17.i1.111165
Published online Jan 15, 2026. doi: 10.4239/wjd.v17.i1.111165
Figure 7 Altered serum levels and diagnostic significance of prostaglandin endoperoxide synthase 2 and microRNA-335-3p in diabetic osteoporosis.
A: Comparison of serum prostaglandin endoperoxide synthase 2 levels between the type 2 diabetes and diabetic osteoporosis groups; B: Comparison of serum microRNA (miR)-335-3p levels between the type 2 diabetes and diabetic osteoporosis groups; C: Correlation analysis of serum prostaglandin endoperoxide synthase 2 with miR-335-3p; D: Receiver operating characteristic curve analysis of miR-335-3p. aP < 0.05. DM: Patients with type 2 diabetes; DOP: Patients with type 2 diabetes with osteoporosis; miR: MicroRNA; PTGS2: Prostaglandin endoperoxide synthase 2; AUC: Area under the curve; CI: Confidence interval.
- Citation: Shao C, Zhang LJ, Song YL, Wang YQ, Zha XJ, Li J, Ye CS, Chen LL, Chen MW, Jin GX. Endothelial cell-derived exosomes inhibit high glucose-induced osteoblast ferroptosis by activating microRNA-335-3p/prostaglandin endoperoxide synthase 2. World J Diabetes 2026; 17(1): 111165
- URL: https://www.wjgnet.com/1948-9358/full/v17/i1/111165.htm
- DOI: https://dx.doi.org/10.4239/wjd.v17.i1.111165